Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1321 to 1335 of 1370 results for patients and public

  1. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  3. Surgical correction of hallux valgus using minimal access techniques

    In development [GID-IPG10339] Expected publication date: 20 June 2024

    Interventional procedures guidance
    In development

  4. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  7. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  8. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  10. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  12. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  13. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis TS ID 12016

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development